News
-
-
-
PRESS RELEASE
AFYREN and Terrial renew their partnership for French-manufactured potash fertilizers
AFYREN and Terrial renew their strategic partnership to supply French-manufactured potash fertilizers, aiming to enhance sustainability in French agriculture and reduce dependencies on international markets -
-
-
PRESS RELEASE
Carbios and the Fiber-to-Fiber Consortium successfully validate the industrial-scale production of recycled polyester T-shirts made from complex plastic and textile waste.
Carbios and the Fiber-to-Fiber Consortium validate industrial-scale production of recycled polyester T-shirts from plastic and textile waste, demonstrating circularity and quality in European manufacturing -
PRESS RELEASE
Carbios et le Consortium «fiber-to-fiber» valident la production industrielle de t-shirts en polyester recyclé fabriqués à partir de déchets plastiques et textiles complexes.
Carbios et le Consortium 'fiber-to-fiber' valident la production industrielle de t-shirts en polyester recyclé à partir de déchets plastiques et textiles complexes. Avancée majeure pour une économie circulaire dans l'industrie textile -
PRESS RELEASE
Rexel announces the success of its c. €500 million Capital Increase, without shareholders’ preferential subscription right, to partially fund the acquisition of GCG
Rexel successfully completes c. €500 million Capital Increase via accelerated bookbuilding to fund GCG acquisition. Proceeds aim at preserving credit rating and financial flexibility. Key terms and timetable detailed -
PRESS RELEASE
Rexel annonce le succès de son augmentation de capital d’environ 500 millions d’euros, avec suppression du droit préférentiel de souscription des actionnaires, afin de financer en partie l’acquisition de GCG
Rexel annonce réussite augmentation capital 500 millions euros financement acquisition GCG. Actions nouvelles émises suppression droit préférentiel souscription -
PRESS RELEASE
Medios sets out Ambition 2031: €3.1 billion revenue and a doubling of EBITDA adjusted
Medios reveals Ambition 2031 to achieve €3.1 billion revenue and double EBITDA by focusing on core business models: Specialty Pharma Supply and Compounding. Strategy emphasizes operational excellence and growth through M&A
